Staff in the U.S. Food and Drug Administration’s Office of New Drugs (OND) began 2020 with a focus on completing the office’s reorganization, but they quickly shifted focus to the global pandemic and supporting accelerated development of new therapeutics to prevent or treat COVID-19, according to the OND’s inaugural annual report.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,